Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00826111 · ClinicalTrials.gov registry record · Phase 4
The Effects of Eszopiclone and Lexapro on Prefrontal Glutamate and GABA in Depression With Anxiety and Insomnia
A Phase 4 study, sponsored by Steward St. Elizabeth's Medical Center of Boston.
- Completed
- Registry status
- Phase 4
- Development phase
- 19
- Enrollment target
NCT00826111 is a Phase 4 study that has completed, run by Steward St. Elizabeth's Medical Center of Boston. The registered enrollment target is 19 participants.
The verdict
NCT00826111, a Phase 4 study, has completed, sponsored by Steward St. Elizabeth's Medical Center of Boston.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 19 participants
- Enrollment target
Study Summary
The study examined the effects of adding the sleep aid eszopiclone to Lexapro on mood and levels of the neurotransmitters glutamate, glutamine, and GABA in women with depression, anxiety, and insomnia. Specifically, the objective was to determine the role of glutamate, glutamine, and GABA in mediating the response the to the combined treatment. The hypothesis was that levels of glutamine and glutamate will be increased in women receiving eszopiclone compared to those receiving placebo. The antidepressant effect of the medication combination and its effect on sleep status was also assessed.
Interventions
- DRUG Placebo
- DRUG Eszopiclone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2007-08 |
| Est. Completion | 2011-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00826111
The ClinicalTrials.gov registry entry for NCT00826111 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Steward St. Elizabeth's Medical Center of Boston, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00826111 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00826111 about?
NCT00826111 is a clinical study titled "The Effects of Eszopiclone and Lexapro on Prefrontal Glutamate and GABA in Depression With Anxiety and Insomnia". The study examined the effects of adding the sleep aid eszopiclone to Lexapro on mood and levels of the neurotransmitters glutamate, glutamine, and GABA in women with depression, anxiety, and insomnia. Specifically, the objective was to determine the role of glutamate, glutamine, and GABA in mediati...
What is the current status of trial NCT00826111?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 19 participants. The study started on 2007-08. Estimated completion is 2011-07.
What interventions are being tested in trial NCT00826111?
The interventions under investigation include: Placebo (DRUG), Eszopiclone (DRUG).
Who is sponsoring clinical trial NCT00826111?
This trial is sponsored by Steward St. Elizabeth's Medical Center of Boston, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.